- Expanded alliance includes an agreement on eco social
collaboration to jointly foster more sustainable diagnostic
solutions, and the renewal of an agreement on hematology solutions
for commercial and hospital laboratories, complementing the Roche
Diagnostics portfolio
- 25-year partnership between Roche and Sysmex brings
hematology testing innovations to laboratories and helps patients
get access to routine hematology diagnostics solutions
BASEL, Switzerland,
Aug. 3, 2023 /PRNewswire/ -- Roche
(SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion of their
Global Business Partnership Agreement with Sysmex. As part of the
renewed framework, the companies strengthen their commitment to
their long-standing partnership. Roche has been collaborating with
Sysmex for 25 years and through the renewed terms, Roche will
continue to offer Sysmex' hematology products, complementing their
total lab solutions portfolio.
The updated non-exclusive agreement also introduces a new area
of collaboration with an additional eco-social agreement to jointly
explore more sustainable diagnostic solutions. By taking their
long-standing collaboration beyond the current portfolio, both
companies are committed to pursue more sustainable solutions.
"We are delighted to expand our 25-year partnership with Sysmex
in the area of hematology and in exploring more sustainable
diagnostics solutions. Roche and Sysmex both have a long-standing
history of delivering reliable and innovative solutions for
patients and I am very happy to see this collaboration grow," said
Matt Sause, CEO of Roche
Diagnostics.
"We are pleased to announce the renewal of our partnership with
Roche, reaffirming our commitment to long-term collaboration.
Developing our partnerships in the field of diagnostics even
further and addressing enduring eco-social challenges represents a
significant milestone in advancing our alliance to the next level.
Together, we firmly believe in making even greater contributions to
our customers in laboratories and creating a sustainable society,"
said Kaoru Asano, President of
Sysmex Corporation.
About the partnership
Roche and Sysmex entered
into their commercial and R&D collaboration in 1998 and
continuously expanded their strong partnership. In 2020, the two
companies signed the Global Business Partnership Agreement to
further expand their partnership and to improve customer
experience. In 2023, with renewed terms and expanded scope, both
companies confirm their long-standing partnership and their
commitment to build a more sustainable future for society.
Roche is committed to supporting improvements in haematology
testing, which helps patients with the diagnosis and management of
blood diseases, as diverse as anaemia and leukaemia. In the
European Union (EU) alone, approximately 80 million people are
currently affected with blood disorders. The burden of blood
disorders on European society is estimated at €23 billion per
year1. The Global Business Partnership
Agreement between Roche and Sysmex stands to benefit patients in
need of diagnostic solutions and will help laboratories to
streamline their testing efficiency and effectiveness through
integrated IVD technologies from a single service provider.
About Roche
Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavor to pursue a long-term perspective in
all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the thirteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche
is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
References
[1] Engert et al. EHA Roadmap for European
Hematology Research. The European Hematology Association Roadmap
for European Hematology Research: a consensus document.
Haematologica. 2016;101(2): 115-208. doi:
10.3324/haematol.2015.136739.
For further information please contact
Euan Cameron, Head
of Communications, Core Lab, Roche Diagnostics Solutions
Phone: + 79 948 54 49 e-Mail:
euan.cameron@roche.com
|
Karin Freyenmuth,
Head of Communications, Roche Diagnostics Partnering
Phone: + 79 578 49 75 e-Mail:
karin.freyenmuth@roche.com
|
View original
content:https://www.prnewswire.co.uk/news-releases/roche-expands-long-term-alliance-with-sysmex-301892152.html